Alzheimer disease: Statins in the treatment of Alzheimer disease

Nature Reviews Neurology

Volumn 7, Issue 12, 2011, Pages 662-663

  Sparks, D Larry ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; DONEPEZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COGNITION; DRUG DOSE INCREASE; DRUG EFFICACY; GENOTYPE; HUMAN; MEDICAL ETHICS; MILD COGNITIVE IMPAIRMENT; PATIENT SELECTION; PRIORITY JOURNAL; RISK REDUCTION;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 83055186684     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2011.165     Document Type: Article

References (10)

1. Sano, M. et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77, 556-563 (2011).
2. Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III final report). NIH National Heart Blood and Lung Institute [online], http://www.nhlbi.nih.gov/guidelines/ cholesterol/atp3-rpt.htm (2002).
3. Sparks, D. L. et al. Atorvastatin for the treatment of mild-to-moderate Alzheimer's disease: preliminary results. Arch. Neurol. 62, 753-757 (2005). (Pubitemid 40656090)
4. Sparks, D. L. et al. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 5, 416-421 (2008).
5. Sparks, D. L. et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener. Dis. 7, 183-186 (2010).
6. Bettermann, K. et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J. Stroke Cerebrovasc. Dis. http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2010.11.002.
7. Feldman, H. H. et al. Randomized controlled trial of atorvastatin in mild-to-moderate Alzheimer's disease: LEADe. Neurology 74, 956-964 (2010).
8. Feldman, H. H. et al. The LEADe Study: a randomized controlled trial investigating the effect of atorvastatin on cognitive and global function in patients with mild to moderate AD receiving background therapy of donepezil [abstract LBS.005]. Neurology 71, 54 (2008).
9. Sparks, D. L. et al. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in AD: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta. Neurol. Scand. 114, 3-7 (2006). (Pubitemid 44015218)
10. Sparks, D. L. et al. The atorvastatin/donepezil in Alzheimer's disease (LEADe) study: effect of atorvastatin on Alzheimer's disease progression by ApoE4 genotype. Presented at the International Conference on Alzheimer's Disease (2008).